Significant Correlation between Polymorphisms of UGT1A1 Gene andLow Irinotecan Toxicity in Colorectal Cancer Patients with FOLFIRI

Hsiang-LinTsai; Chin-FanChen; Chien-YuLu; Wei-YuFang; Deng-ChyangWu; I-ChenWu; Maw-ChangSheen; Shiu-RuLin; Jaw-Yuan Wang

首页> 外文期刊>The Open Colorectal Cancer Journal >Significant Correlation between Polymorphisms of UGT1A1 Gene andLow Irinotecan Toxicity in Colorectal Cancer Patients with FOLFIRI

【24h】

Significant Correlation between Polymorphisms of UGT1A1 Gene andLow Irinotecan Toxicity in Colorectal Cancer Patients with FOLFIRI

机译：大肠癌FOLFIRI患者UGT1A1基因多态性与伊立替康低毒性的显着相关性

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Open Colorectal Cancer Journal》 |2009年第1期|共6页
作者
Hsiang-LinTsai; Chin-FanChen; Chien-YuLu; Wei-YuFang; Deng-ChyangWu; I-ChenWu; Maw-ChangSheen; Shiu-RuLin; Jaw-Yuan Wang;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类针灸疗法临床应用;
关键词
入库时间 2022-08-18 15:06:13

相似文献

外文文献
中文文献
专利

1. UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF -Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI [J] . Yi-Chien Hsieh, Tsung-Kun Chang, Wei-Chih Su, Journal of oncology . 2021,第a期

机译：用一线Bevacizumab和Folfiri治疗BRAF级化转移性结直肠癌患者的伊替康剂量升级的UGT1A1多态性
2. Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial [J] . Yung-Sung Yeh, Hsiang-Lin Tsai, Ching-Wen Huang, Trials . 2016,第1期

机译：UGT1A1启动子多态性用于贝伐单抗联合FOLFIRI作为一线治疗的转移性结直肠癌患者中伊立替康剂量递增的前瞻性研究：一项随机对照试验的研究方案
3. Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting [J] . Chien-Yu Lu, Ching-Wen Huang, I-Chen Wu, Translational Oncology . 2015,第6期

机译：贝伐单抗联合FOLFIRI治疗一线治疗中 UGT1A1 启动子多态性对伊立替康剂量递增的转移性结直肠癌患者的临床意义
4. Reprimo 824 G>C and p53R2 4696 G>C Single Nucleotide Polymorphisms in Healthy, Diverticular Disease and Colorectal Cancer Populations [C] . W. Beasle European Society for Surgical Research . 2005

机译：谴责824g> c和p53r2 4696 g> c健康，憩室疾病和结直肠癌种群中的单核苷酸多态性
5. Use and outcomes of newer chemotherapeutic agents in colorectal cancer patients using Irinotecan as a case study. [D] . Obeidat, Nour A. 2008

机译：以伊立替康为例的结直肠癌患者中新型化疗药物的使用和结果。
6. UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI [O] . Yi-Chien Hsieh, Tsung-Kun Chang, Wei-Chih Su, 2021

机译：用一线Bevacizumab和Folfiri治疗Braf-突变转移性结肠直肠癌患者的伊替康剂量升级的UGT1A1多态性
7. UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI [O] . Yi-Chien Hsieh, Tsung-Kun Chang, Wei-Chih Su, 2021

机译：用一线Bevacizumab和Folfiri治疗Braf-突变转移性结肠直肠癌患者的伊替康剂量升级的UGT1A1多态性

Significant Correlation between Polymorphisms of UGT1A1 Gene andLow Irinotecan Toxicity in Colorectal Cancer Patients with FOLFIRI

著录项

相似文献

相关主题

期刊订阅